Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon Koo Kang, Li Tzong Chen, Min Hee Ryu, Do Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen Shi Chen, Li Yuan Bai, Sung Yong Oh, Yasuhiro ChodaHisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku
Dive into the research topics of 'Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.